ArticleMovement disorders clinical practice2026
Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnxiety, fatigue, and excessive daytime sleepiness (EDS) frequently co-occur in Parkinson's disease (PD) and can influence the clinical determination of apathy.
objectiveTo distinguish patient-reported apathy from other non-motor symptoms.
methodsIndividuals with PD meeting UK Brain Bank criteria underwent paired OFF- and ON- dopaminergic medication assessments, including the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Hamilton Anxiety and Depression Rating Scales (HAM-A, HAM-D), Symbol Digit Modalities Test, Stroop, and Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction assessment. Medication-related changes in anxiety, depression, and cognition were defined using established minimally clinically important differences. Apathy, fatigue, and sleepiness were determined based on MDS-UPDRS Part I scores ≥1. Associations were examined using chi-squared tests, multivariable ordinal logistic regression, and symptom-network analyses.
resultsAmong 199 participants (36-85 years, 61% male), 90% (53/59) of those with apathy also reported both fatigue and sleepiness. Exploratory network analysis grouped apathy with anxiety and depression, whereas fatigue clustered with somatic symptoms (eg, pain, constipation) and daytime sleepiness remained peripheral. Apathy was independently associated with medication-related change in anxiety after adjustment for fatigue and sleepiness (P < 0.001), while fatigue was associated with autonomic dysfunction (P < 0.05).
conclusionDespite overlapping presentation, apathy in PD closely tracks affective change linked to dopaminergic state, whereas fatigue and sleepiness reflect broader somatic burden. These distinctions may support more specific recognition and phenotyping of apathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.